Biological effects of induction immunosuppression

Current Opinion in Immunology

Volumn 16, Issue 5, 2004, Pages 565-570

  Hale, Douglas A ^a  

^a Natl Inst Diabet Digest K   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; IMMUNOGLOBULIN; OKT 3; THYMOCYTE ANTIBODY;

ANTIGEN PRESENTING CELL; HISTOCOMPATIBILITY; HOMEOSTASIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE; MOLECULAR CLONING; MOLECULAR RECOGNITION; MONONUCLEAR CELL; NONHUMAN; REVIEW;

ANIMALS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; TRANSPLANTATION TOLERANCE;

EID: 4444252604     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2004.07.005     Document Type: Review

References (58)

1. L.M. Rebellato, U. Gross, K.M. Verbanac, and J.M. Thomas A comprehensive definition of the major antibody specificities in polyclonal rabbit antithymocyte globulin Transplantation 57 1994 685 694
2. N. Bonnefoy-Berard, C. Vincent, and J.P. Revillard Antibodies against functional leukocyte surface molecules in polyclonal antilymphocyte and antithymocyte globulins Transplantation 51 1991 669 673
3. J.R. Thistlethwaite Jr., J.K. Stuart, J.T. Mayes, A.O. Gaber, S. Woodle, M.R. Buckingham, and F.P. Stuart Complications and monitoring of OKT3 therapy Am J Kidney Dis 11 1988 112 119
4. H.F. Welter, W.D. Illner, S. Schleibner, D. Abendroth, E. Hancke, J. Groh, and W. Land Pilot study on induction treatment with high-dose OKT3: preliminary observations in kidney transplantation Transplant Proc 22 1990 2272
5. N. Bonnefoy-Berard, and J.P. Revillard Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3 J Heart Lung Transplant 15 1996 435 442
6. N.Z. Galante, N.O. Camara, E.G. Kallas, R. Salomao, and A. Pacheco-Silva Modulation of peripheral blood T-lymphocytes in kidney transplant recipients treated with low dose OKT3 therapy Immunol Lett 91 2004 75 77
7. S. Caillat-Zucman, N. Blumenfeld, C. Legendre, L.H. Noel, J.F. Bach, H. Kreis, and L. Chatenoud The OKT3 immunosuppressive effect. In situ antigenic modulation of human graft-infiltrating T cells Transplantation 49 1990 156 160
8. L. Chatenoud, M.F. Baudrihaye, H. Kreis, G. Goldstein, J. Schindler, and J.F. Bach Human in vivo antigenic modulation induced by the anti-T cell OKT3 monoclonal antibody Eur J Immunol 12 1982 979 982
9. J.P. Van Wauwe, J.R. De Mey, and J.G. Goossens OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties J Immunol 124 1980 2708 2713
10. D. Simpson T-cell depleting antibodies: new hope for induction of allograft tolerance in bone marrow transplantation? BioDrugs 17 2003 147 154
11. R. Calne, P. Friend, S. Moffatt, A. Bradley, G. Hale, J. Firth, J. Bradley, K. Smith, and H. Waldmann Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients Lancet 351 1998 1701 1702
12. A.D. Kirk, D.A. Hale, R.B. Mannon, D.E. Kleiner, S.C. Hoffmann, R.L. Kampen, L.K. Cendales, D.K. Tadaki, D.M. Harlan, and S.J. Swanson Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H) Transplantation 76 2003 120 129
13. G. Hale, T. Hoang, T. Prospero, S.M. Watt, and H. Waldmann Removal of T cells from bone marrow for transplantation. Comparison of rat monoclonal anti-lymphocyte antibodies of different isotypes Mol Biol Med 1 1983 305 319
14. G. Hale, S. Bright, G. Chumbley, T. Hoang, D. Metcalf, A.J. Munro, and H. Waldmann Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement Blood 62 1983 873 882
15. M.J. Dyer, G. Hale, F.G. Hayhoe, and H. Waldmann Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype Blood 73 1989 1431 1439
16. P. Klangsinsirikul, G.I. Carter, J.L. Byrne, G. Hale, and N.H. Russell Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution Blood 99 2002 2586 2591
17. G. Ratzinger, J.L. Reagan, G. Heller, K.J. Busam, and J.W. Young Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation Blood 101 2003 1422 1429
18. T.E. Starzl, T.L. Marchioro, D.E. Hutchinson, K.A. Porter, G.J. Cerilli, and L. Brettschneider The clinical use of antilymphocyte globulin in renal homotransplantation Transplantation 5 Suppl 5 1967 1100 1105
19. D.C. Brennan, K. Flavin, J.A. Lowell, T.K. Howard, S. Shenoy, S. Burgess, S. Dolan, J.M. Kano, M. Mahon, and M.A. Schnitzler A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients Transplantation 67 1999 1011 1018
20. M. Buchler, D.L. Hurault, C. Madec, and Y. Lebranchu Induction therapy by anti-thymocyte globulin (rabbit) in renal transplantation: a 1-yr follow-up of safety and efficacy Clin Transplant 17 2003 539 545
21. A.O. Gaber, M.R. First, R.J. Tesi, R.S. Gaston, R. Mendez, L.L. Mulloy, J.A. Light, L.W. Gaber, E. Squiers, and R.J. Taylor Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation Transplantation 66 1998 29 37
22. W.C. Goggins, M.A. Pascual, J.A. Powelson, C. Magee, N. Tolkoff-Rubin, M.L. Farrell, D.S. Ko, W.W. Williams, A. Chandraker, and F.L. Delmonico A prospective, randomized, clinical trial of intraoperative versus postoperative Thymoglobulin in adult cadaveric renal transplant recipients Transplantation 76 2003 798 802
23. T.F. Mueller, S.O. Grebe, M.C. Neumann, J. Heymanns, K. Radsak, H. Sprenger, and H. Lange Persistent long-term changes in lymphocyte subsets induced by polyclonal antibodies Transplantation 64 1997 1432 1437
24. X. Preville, M. Flacher, B. LeMauff, S. Beauchard, P. Davelu, J. Tiollier, and J.P. Revillard Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model Transplantation 71 2001 460 468
25. L. Genestier, S. Fournel, M. Flacher, O. Assossou, J.P. Revillard, and N. Bonnefoy-Berard Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins Blood 91 1998 2360 2368
26. M. Lenardo, K.M. Chan, F. Hornung, H. McFarland, R. Siegel, J. Wang, and L. Zheng Mature T lymphocyte apoptosis - immune regulation in a dynamic and unpredictable antigenic environment Annu Rev Immunol 17 1999 221 253
27. M.C. Michallet, F. Saltel, X. Preville, M. Flacher, J.P. Revillard, and L. Genestier Cathepsin-B-dependent apoptosis triggered by antithymocyte globulins: a novel mechanism of T-cell depletion Blood 102 2003 3719 3726
28. J.S. Bourdage, and D.M. Hamlin Comparative polyclonal antithymocyte globulin and antilymphocyte/antilymphoblast globulin anti-CD antigen analysis by flow cytometry Transplantation 59 1995 1194 1200
29. M.C. Michallet, X. Preville, M. Flacher, S. Fournel, L. Genestier, and J.P. Revillard Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins Transplantation 75 2003 657 662 This study documents the functional effects of the blockade or modulation of adhesion molecules mediated by ATG preparations on leukocyte chemotaxis.
30. K.B. Gordon, K.A. Papp, T.K. Hamilton, P.A. Walicke, W. Dummer, N. Li, B.W. Bresnahan, and A. Menter Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial J Am Med Assoc 290 2003 3073 3080
31. M. Lebwohl, S.K. Tyring, T.K. Hamilton, D. Toth, S. Glazer, N.H. Tawfik, P. Walicke, W. Dummer, X. Wang, M.R. Garovoy, and D. Pariser A novel targeted T-cell modulator, efalizumab, for plaque psoriasis N Engl J Med 349 2003 2004 2013
32. R.L. Dedrick, S. Bodary, and M.R. Garovoy Adhesion molecules as therapeutic targets for autoimmune diseases and transplant rejection Expert Opin Biol Ther 3 2003 85 95
33. G. Klaus, K. Mostert, B. Reckzeh, and T.F. Mueller Phenotypic changes in lymphocyte subpopulations in pediatric renal-transplant patients after T-cell depletion Transplantation 76 2003 1719 1724
34. M. Oertel, U. Sack, K. Kohlhaw, I. Lehmann, F. Emmrich, F. Berr, J. Hauss, and R. Schwarz Induction therapy including antithymocyte globulin induces marked alterations in T lymphocyte subpopulations after liver transplantation: results of a long-term study Transplant Int 15 2002 463 471
35. A.E. Troy, and H. Shen Cutting edge: homeostatic proliferation of peripheral T lymphocytes is regulated by clonal competition J Immunol 170 2003 672 676 First study to describe the regulatory effect of T cell clonality on homeostatic repopulation.
36. B. Min, G. Foucras, M. Meier-Schellersheim, and W.E. Paul Spontaneous proliferation, a response of naive CD4 T cells determined by the diversity of the memory cell repertoire Proc Natl Acad Sci USA 101 2004 3874 3879
37. Z. Wu, S.J. Bensinger, J. Zhang, C. Chen, X. Yuan, X. Huang, J.F. Markmann, A. Kassaee, B.R. Rosengard, and W.W. Hancock Homeostatic proliferation is a barrier to transplantation tolerance Nat Med 10 2004 87 92 This study reports that, having completed the process of homeostatic proliferation, T cells are resistant to the induction of tolerance. This observation has broad implications for the application of depletional agents in tolerance induction regimens.
38. A.M. Jamieson, P. Isnard, J.R. Dorfman, M.C. Coles, and D.H. Raulet Turnover and proliferation of NK cells in steady state and lymphopenic conditions J Immunol 172 2004 864 870
39. M. Prlic, B.R. Blazar, M.A. Farrar, and S.C. Jameson In vivo survival and homeostatic proliferation of natural killer cells J Exp Med 197 2003 967 976 First study to demonstrate that NK cells undergo a homeostatic proliferation analogous to that observed for T cells under lymphopenic conditions.
40. D. Adu, P. Cockwell, N.J. Ives, J. Shaw, and K. Wheatley Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials Br Med J 326 2003 789 791
41. A.C. Webster, E.G. Playford, G. Higgins, J.R. Chapman, and J.C. Craig Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials Transplantation 77 2004 166 176
42. X.C. Li, P. Roy-Chaudhury, W.W. Hancock, R. Manfro, M.S. Zand, Y. Li, X.X. Zheng, P.W. Nickerson, J. Steiger, T.R. Malek, and T.B. Strom IL-2 and IL-4 double knockout mice reject islet allografts: a role for novel T cell growth factors in allograft rejection J Immunol 161 1998 890 896
43. B. Kircher, K. Latzer, G. Gastl, and D. Nachbaur Comparative in vitro study of the immunomodulatory activity of humanized and chimeric anti-CD25 monoclonal antibodies Clin Exp Immunol 134 2003 426 430
44. J.F. McDyer, Z. Li, S. John, X. Yu, C.Y. Wu, and J.A. Ragheb IL-2 receptor blockade inhibits late, but not early, IFN-γ and CD40 ligand expression in human T cells: disruption of both IL-12-dependent and -independent pathways of IFN-γ production J Immunol 169 2002 2736 2746
45. C.C. Baan, I.C. Riemsdijk-Overbeeke, M.J. Boelaars-van Haperen, J.M. IJzermans, and W. Weimar Inhibition of the IL-15 pathway in anti-CD25 mAb treated renal allograft recipients Transplant Immunol 10 2002 81 87
46. K.J. Woodside, M. Hu, T. Meng, G.C. Hunter, L.E. Sower, and J.A. Daller Differential effects of interleukin-2 blockade on apoptosis in naive and activated human lymphocytes Transplantation 75 2003 1631 1635
47. E. Akalin, S. Ames, V. Sehgal, M. Fotino, L. Daly, B. Murphy, and J.S. Bromberg Intravenous immunoglobulin and thymoglobulin facilitate kidney transplantation in complement-dependent cytotoxicity B-cell and flow cytometry T- or B-cell crossmatch-positive patients Transplantation 76 2003 1444 1447
48. R.A. Montgomery, A.A. Zachary, L.C. Racusen, M.S. Leffell, K.E. King, J. Burdick, W.R. Maley, and L.E. Ratner Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients Transplantation 70 2000 887 895
49. P. Imbach, S. Barandun, V. d'Apuzzo, C. Baumgartner, A. Hirt, A. Morell, E. Rossi, M. Schoni, M. Vest, and H.P. Wagner High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood Lancet 1 1981 1228 1231
50. I. Knezevic-Maramica, and M.S. Kruskall Intravenous immune globulins: an update for clinicians Transfusion 43 2003 1460 1480
51. D. Cavill, S.A. Waterman, and T.P. Gordon Antiidiotypic antibodies neutralize autoantibodies that inhibit cholinergic neurotransmission Arthritis Rheum 48 2003 3597 3602
52. M. Basta, P. Kirshbom, M.M. Frank, and L.F. Fries Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model J Clin Invest 84 1989 1974 1981
53. M. Basta, P.F. Langlois, M. Marques, M.M. Frank, and L.F. Fries High-dose intravenous immunoglobulin modifies complement-mediated in vivo clearance Blood 74 1989 326 333
54. Z. Yu, and V.A. Lennon Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases N Engl J Med 340 1999 227 228
55. J. Bayry, S. Lacroix-Desmazes, C. Carbonneil, N. Misra, V. Donkova, A. Pashov, A. Chevailler, L. Mouthon, B. Weill, and P. Bruneval Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin Blood 101 2003 758 765 First study to document the inhibitory effect of IVIG on antigen-presenting cells, thus adding yet another layer of complexity to the known immunomodulatory properties of this agent.
56. C.J. Rhoades, M.A. Williams, S.M. Kelsey, and A.C. Newland Monocyte-macrophage system as targets for immunomodulation by intravenous immunoglobulin Blood Rev 14 2000 14 30
57. T. Ichiyama, Y. Ueno, M. Hasegawa, A. Niimi, T. Matsubara, and S. Furukawa Intravenous immunoglobulin inhibits NF-κB activation and affects Fcγ receptor expression in monocytes/macrophages Naunyn Schmiedebergs Arch Pharmacol 369 2004 428 433
58. J. Bayry, M. Thirion, N. Misra, N. Thorenoor, S. Delignat, S. Lacroix-Desmazes, B. Bellon, S. Kaveri, and M.D. Kazatchkine Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases Neurol Sci 24 Suppl 4 2003 S217 S221